Tag Archives: Martin Landry

Cipher Pharma Gets a Buy Rating from GMP FirstEnergy

Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. GMP FirstEnergy’s analyst Martin Landry reiterates their Buy rating on the shares of Cipher Pharma (TSX: CPH), with a C$7

GMP FirstEnergy Reiterates a Buy Rating on Knight Therapeutics

Knight Therapeutics (TSX: GUD), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. Analyst Martin Landry from GMP FirstEnergy reiterated a Buy rating, with a C$10 price target. According to TipRanks.com, Landry

GMP FirstEnergy Thinks Cipher Pharma’s Stock is Going to Recover

In a new note to investors today, an analyst has provided a rating update for the Healthcare company, Cipher Pharma (TSX: CPH). Analyst Martin Landry from GMP FirstEnergy remains bullish on the stock and has a C$8 price target. According

GMP FirstEnergy Sticks to Its Hold Rating for Aimia Inc.

Wall Street analyst has provided a review for the Services company today, but retained the same rating on the stock. Analyst Martin Landry from GMP FirstEnergy rated Aimia Inc. (TSX: AIM) a Hold, setting a C$2.75 price target. According to

Cronos Group Inc was Downgraded to a Hold Rating at GMP FirstEnergy

Cronos Group Inc (TSXV: MJN), the Financial sector company, has received a rating update from a Wall Street analyst today. GMP FirstEnergy’s analyst Martin Landry expressed some doubt about the stock, as it was downgraded to Hold with a C$11

BRP Inc. SV Receives a Buy from GMP FirstEnergy

Wall Street analyst has provided a review for the Consumer Goods company on December 4, but retained the same rating on the stock. On December 4, analyst Martin Landry gave a Buy rating to DOO and set a C$53 price